Hematopoietic stem cell transplantation in Egypt

Hematopoietic SCT is now an established treatment modality with definitive indications for many hematological disorders. However, this line of treatment requires tremendous resources, and it becomes increasingly difficult for transplanters practicing in the developing world to reconcile the differen...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bone marrow transplantation (Basingstoke) 2008-08, Vol.42 (Suppl 1), p.S76-S80
Hauptverfasser: Mahmoud, H K, El-Haddad, A M, Fahmy, O A, El-Emary, M, Nassar, A, Abdel-Mooti, M, Sobhy, A, Sultan, A
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page S80
container_issue Suppl 1
container_start_page S76
container_title Bone marrow transplantation (Basingstoke)
container_volume 42
creator Mahmoud, H K
El-Haddad, A M
Fahmy, O A
El-Emary, M
Nassar, A
Abdel-Mooti, M
Sobhy, A
Sultan, A
description Hematopoietic SCT is now an established treatment modality with definitive indications for many hematological disorders. However, this line of treatment requires tremendous resources, and it becomes increasingly difficult for transplanters practicing in the developing world to reconcile the difference between what is possible and what is available. On the basis of 18 years of experience and more than 1300 transplants, this article will focus on special issues, which we think are important for hematopoietic SCT practices in developing countries, taking the program in Egypt as an example that may be applicable to other countries in the developing world. The SCT program in Egypt started in 1989 on a narrow scale. In 1997, the transplant rate increased dramatically with the opening of the SCT unit at the Nasser Institute. Our team is registered in the Center for International Blood and Marrow Transplant Research. The total number of transplants performed till June 2007 is 1362; 80% of the cases are allogeneic and 20% autologous. There are seven other centers in Egypt performing mainly autologous transplants.
doi_str_mv 10.1038/bmt.2008.136
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_69457376</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A185292758</galeid><sourcerecordid>A185292758</sourcerecordid><originalsourceid>FETCH-LOGICAL-c546t-e03634b6c69ef07f04acde5943809f33121fdc226d73de529658753355f7b73f3</originalsourceid><addsrcrecordid>eNp1kc1P3DAQxS1EBQvtjXMVgcSp2fpznBwRolAJqZf2bHkdezFK7DR2Dvz3ONqVtiAqHyyNf_P8Zh5CFwSvCWbN982Q1xTjZk0YHKEV4RJqwUAcoxWm0NSMQXuKzlJ6xphwjsUJOiWNpJwRskL4wQ46xzF6m72pUrZDZWzfV3nSIY29DllnH0PlQ3W3fRnzZ_TJ6T7ZL_v7HP35cff79qF-_HX_8_bmsTaCQ64tZsD4Bgy01mHpMNems6LlrMGtY4xQ4jpDKXSSlTptQTRSMCaEkxvJHDtH1zvdcYp_Z5uyGnxanOlg45wUtFxIJqGAV-_A5zhPoXhTFDglIAgWhbr8L0UAgBJODlJb3Vvlg4tlC2b5V92QppikUjSFWn9AldPZwZsYrPOl_qbh-p-GJ6v7_JRiPy97TW_BbzvQTDGlyTo1Tn7Q04siWC1hqxK2WsJWJeyCf93PNG8G2x3gfboFqHdAKk9ha6fD0B8KvgKK5K5Z</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>216662141</pqid></control><display><type>article</type><title>Hematopoietic stem cell transplantation in Egypt</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>Nature Journals Online</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Mahmoud, H K ; El-Haddad, A M ; Fahmy, O A ; El-Emary, M ; Nassar, A ; Abdel-Mooti, M ; Sobhy, A ; Sultan, A</creator><creatorcontrib>Mahmoud, H K ; El-Haddad, A M ; Fahmy, O A ; El-Emary, M ; Nassar, A ; Abdel-Mooti, M ; Sobhy, A ; Sultan, A</creatorcontrib><description>Hematopoietic SCT is now an established treatment modality with definitive indications for many hematological disorders. However, this line of treatment requires tremendous resources, and it becomes increasingly difficult for transplanters practicing in the developing world to reconcile the difference between what is possible and what is available. On the basis of 18 years of experience and more than 1300 transplants, this article will focus on special issues, which we think are important for hematopoietic SCT practices in developing countries, taking the program in Egypt as an example that may be applicable to other countries in the developing world. The SCT program in Egypt started in 1989 on a narrow scale. In 1997, the transplant rate increased dramatically with the opening of the SCT unit at the Nasser Institute. Our team is registered in the Center for International Blood and Marrow Transplant Research. The total number of transplants performed till June 2007 is 1362; 80% of the cases are allogeneic and 20% autologous. There are seven other centers in Egypt performing mainly autologous transplants.</description><identifier>ISSN: 0268-3369</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/bmt.2008.136</identifier><identifier>PMID: 18724311</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Autografts ; beta-Thalassemia - therapy ; Blood diseases ; Bone marrow ; Care and treatment ; Cell Biology ; Developing countries ; Egypt ; Follow-Up Studies ; Health aspects ; Hematological diseases ; Hematology ; Hematopoietic Stem Cell Transplantation - adverse effects ; Hematopoietic stem cells ; Histocompatibility Testing ; Humans ; Internal Medicine ; LDCs ; Leukemia - therapy ; Medicine ; Medicine &amp; Public Health ; Public Health ; review ; Socioeconomic Factors ; Statistics ; Stem cell transplantation ; Stem Cells ; Transplantation ; Transplantation of organs, tissues, etc ; Transplants ; Transplants &amp; implants</subject><ispartof>Bone marrow transplantation (Basingstoke), 2008-08, Vol.42 (Suppl 1), p.S76-S80</ispartof><rights>Macmillan Publishers Limited 2008</rights><rights>COPYRIGHT 2008 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Aug 2008</rights><rights>Macmillan Publishers Limited 2008.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c546t-e03634b6c69ef07f04acde5943809f33121fdc226d73de529658753355f7b73f3</citedby><cites>FETCH-LOGICAL-c546t-e03634b6c69ef07f04acde5943809f33121fdc226d73de529658753355f7b73f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/bmt.2008.136$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/bmt.2008.136$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18724311$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mahmoud, H K</creatorcontrib><creatorcontrib>El-Haddad, A M</creatorcontrib><creatorcontrib>Fahmy, O A</creatorcontrib><creatorcontrib>El-Emary, M</creatorcontrib><creatorcontrib>Nassar, A</creatorcontrib><creatorcontrib>Abdel-Mooti, M</creatorcontrib><creatorcontrib>Sobhy, A</creatorcontrib><creatorcontrib>Sultan, A</creatorcontrib><title>Hematopoietic stem cell transplantation in Egypt</title><title>Bone marrow transplantation (Basingstoke)</title><addtitle>Bone Marrow Transplant</addtitle><addtitle>Bone Marrow Transplant</addtitle><description>Hematopoietic SCT is now an established treatment modality with definitive indications for many hematological disorders. However, this line of treatment requires tremendous resources, and it becomes increasingly difficult for transplanters practicing in the developing world to reconcile the difference between what is possible and what is available. On the basis of 18 years of experience and more than 1300 transplants, this article will focus on special issues, which we think are important for hematopoietic SCT practices in developing countries, taking the program in Egypt as an example that may be applicable to other countries in the developing world. The SCT program in Egypt started in 1989 on a narrow scale. In 1997, the transplant rate increased dramatically with the opening of the SCT unit at the Nasser Institute. Our team is registered in the Center for International Blood and Marrow Transplant Research. The total number of transplants performed till June 2007 is 1362; 80% of the cases are allogeneic and 20% autologous. There are seven other centers in Egypt performing mainly autologous transplants.</description><subject>Autografts</subject><subject>beta-Thalassemia - therapy</subject><subject>Blood diseases</subject><subject>Bone marrow</subject><subject>Care and treatment</subject><subject>Cell Biology</subject><subject>Developing countries</subject><subject>Egypt</subject><subject>Follow-Up Studies</subject><subject>Health aspects</subject><subject>Hematological diseases</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation - adverse effects</subject><subject>Hematopoietic stem cells</subject><subject>Histocompatibility Testing</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>LDCs</subject><subject>Leukemia - therapy</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Public Health</subject><subject>review</subject><subject>Socioeconomic Factors</subject><subject>Statistics</subject><subject>Stem cell transplantation</subject><subject>Stem Cells</subject><subject>Transplantation</subject><subject>Transplantation of organs, tissues, etc</subject><subject>Transplants</subject><subject>Transplants &amp; implants</subject><issn>0268-3369</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kc1P3DAQxS1EBQvtjXMVgcSp2fpznBwRolAJqZf2bHkdezFK7DR2Dvz3ONqVtiAqHyyNf_P8Zh5CFwSvCWbN982Q1xTjZk0YHKEV4RJqwUAcoxWm0NSMQXuKzlJ6xphwjsUJOiWNpJwRskL4wQ46xzF6m72pUrZDZWzfV3nSIY29DllnH0PlQ3W3fRnzZ_TJ6T7ZL_v7HP35cff79qF-_HX_8_bmsTaCQ64tZsD4Bgy01mHpMNems6LlrMGtY4xQ4jpDKXSSlTptQTRSMCaEkxvJHDtH1zvdcYp_Z5uyGnxanOlg45wUtFxIJqGAV-_A5zhPoXhTFDglIAgWhbr8L0UAgBJODlJb3Vvlg4tlC2b5V92QppikUjSFWn9AldPZwZsYrPOl_qbh-p-GJ6v7_JRiPy97TW_BbzvQTDGlyTo1Tn7Q04siWC1hqxK2WsJWJeyCf93PNG8G2x3gfboFqHdAKk9ha6fD0B8KvgKK5K5Z</recordid><startdate>20080801</startdate><enddate>20080801</enddate><creator>Mahmoud, H K</creator><creator>El-Haddad, A M</creator><creator>Fahmy, O A</creator><creator>El-Emary, M</creator><creator>Nassar, A</creator><creator>Abdel-Mooti, M</creator><creator>Sobhy, A</creator><creator>Sultan, A</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20080801</creationdate><title>Hematopoietic stem cell transplantation in Egypt</title><author>Mahmoud, H K ; El-Haddad, A M ; Fahmy, O A ; El-Emary, M ; Nassar, A ; Abdel-Mooti, M ; Sobhy, A ; Sultan, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c546t-e03634b6c69ef07f04acde5943809f33121fdc226d73de529658753355f7b73f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Autografts</topic><topic>beta-Thalassemia - therapy</topic><topic>Blood diseases</topic><topic>Bone marrow</topic><topic>Care and treatment</topic><topic>Cell Biology</topic><topic>Developing countries</topic><topic>Egypt</topic><topic>Follow-Up Studies</topic><topic>Health aspects</topic><topic>Hematological diseases</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation - adverse effects</topic><topic>Hematopoietic stem cells</topic><topic>Histocompatibility Testing</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>LDCs</topic><topic>Leukemia - therapy</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Public Health</topic><topic>review</topic><topic>Socioeconomic Factors</topic><topic>Statistics</topic><topic>Stem cell transplantation</topic><topic>Stem Cells</topic><topic>Transplantation</topic><topic>Transplantation of organs, tissues, etc</topic><topic>Transplants</topic><topic>Transplants &amp; implants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mahmoud, H K</creatorcontrib><creatorcontrib>El-Haddad, A M</creatorcontrib><creatorcontrib>Fahmy, O A</creatorcontrib><creatorcontrib>El-Emary, M</creatorcontrib><creatorcontrib>Nassar, A</creatorcontrib><creatorcontrib>Abdel-Mooti, M</creatorcontrib><creatorcontrib>Sobhy, A</creatorcontrib><creatorcontrib>Sultan, A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mahmoud, H K</au><au>El-Haddad, A M</au><au>Fahmy, O A</au><au>El-Emary, M</au><au>Nassar, A</au><au>Abdel-Mooti, M</au><au>Sobhy, A</au><au>Sultan, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hematopoietic stem cell transplantation in Egypt</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><stitle>Bone Marrow Transplant</stitle><addtitle>Bone Marrow Transplant</addtitle><date>2008-08-01</date><risdate>2008</risdate><volume>42</volume><issue>Suppl 1</issue><spage>S76</spage><epage>S80</epage><pages>S76-S80</pages><issn>0268-3369</issn><eissn>1476-5365</eissn><abstract>Hematopoietic SCT is now an established treatment modality with definitive indications for many hematological disorders. However, this line of treatment requires tremendous resources, and it becomes increasingly difficult for transplanters practicing in the developing world to reconcile the difference between what is possible and what is available. On the basis of 18 years of experience and more than 1300 transplants, this article will focus on special issues, which we think are important for hematopoietic SCT practices in developing countries, taking the program in Egypt as an example that may be applicable to other countries in the developing world. The SCT program in Egypt started in 1989 on a narrow scale. In 1997, the transplant rate increased dramatically with the opening of the SCT unit at the Nasser Institute. Our team is registered in the Center for International Blood and Marrow Transplant Research. The total number of transplants performed till June 2007 is 1362; 80% of the cases are allogeneic and 20% autologous. There are seven other centers in Egypt performing mainly autologous transplants.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>18724311</pmid><doi>10.1038/bmt.2008.136</doi></addata></record>
fulltext fulltext
identifier ISSN: 0268-3369
ispartof Bone marrow transplantation (Basingstoke), 2008-08, Vol.42 (Suppl 1), p.S76-S80
issn 0268-3369
1476-5365
language eng
recordid cdi_proquest_miscellaneous_69457376
source MEDLINE; SpringerLink Journals; Nature Journals Online; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Autografts
beta-Thalassemia - therapy
Blood diseases
Bone marrow
Care and treatment
Cell Biology
Developing countries
Egypt
Follow-Up Studies
Health aspects
Hematological diseases
Hematology
Hematopoietic Stem Cell Transplantation - adverse effects
Hematopoietic stem cells
Histocompatibility Testing
Humans
Internal Medicine
LDCs
Leukemia - therapy
Medicine
Medicine & Public Health
Public Health
review
Socioeconomic Factors
Statistics
Stem cell transplantation
Stem Cells
Transplantation
Transplantation of organs, tissues, etc
Transplants
Transplants & implants
title Hematopoietic stem cell transplantation in Egypt
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T02%3A55%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hematopoietic%20stem%20cell%20transplantation%20in%20Egypt&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=Mahmoud,%20H%20K&rft.date=2008-08-01&rft.volume=42&rft.issue=Suppl%201&rft.spage=S76&rft.epage=S80&rft.pages=S76-S80&rft.issn=0268-3369&rft.eissn=1476-5365&rft_id=info:doi/10.1038/bmt.2008.136&rft_dat=%3Cgale_proqu%3EA185292758%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=216662141&rft_id=info:pmid/18724311&rft_galeid=A185292758&rfr_iscdi=true